Will you recommend abemaciclib in combination with standard adjuvant endocrine therapy in patients with high risk hormone receptor positive, HER2 normal early breast cancer?   

With the recent announcement that the phase 3 MonarchE trial met its primary endpoint. 



Answer from: Medical Oncologist at Community Practice

Answer from: Medical Oncologist at Community Practice

Answer from: Medical Oncologist at Academic Institution